Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Edesa Biotech ( (EDSA) ).
On May 13, 2026, Edesa Biotech’s board approved a change to Chief Executive Officer Pardeep Nijhawan’s compensation structure, allowing 90% of his monthly base salary to be paid in fully vested restricted share units under the company’s 2019 Equity Incentive Compensation Plan, with the remaining 10% paid in cash to meet labor and withholding requirements. This modification, which increases the equity portion from a prior 50% salary-in-RSUs arrangement, further ties the CEO’s compensation to the fair market value of Edesa’s common shares and signals an emphasis on conserving cash while aligning leadership incentives with shareholder value.
The RSUs will be granted monthly based on 90% of Dr. Nijhawan’s base salary divided by the month-end fair market value of the company’s common shares, and will be governed by the terms of the equity plan and applicable award agreement. The decision reflects the flexibility embedded in the amended and restated employment agreement dated August 4, 2023, and underscores a strategic use of equity-based compensation that may influence investor perceptions of the company’s capital allocation and governance practices.
The most recent analyst rating on (EDSA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Edesa Biotech stock, see the EDSA Stock Forecast page.
Spark’s Take on EDSA Stock
According to Spark, TipRanks’ AI Analyst, EDSA is a Neutral.
The score is driven up by strong technical momentum and a meaningful positive Phase 3 update. Offsetting these positives, current fundamentals remain weak with minimal revenue and sustained losses/cash burn, and valuation is constrained by negative earnings.
To see Spark’s full report on EDSA stock, click here.
More about Edesa Biotech
Edesa Biotech, Inc. is a biotechnology company that develops and commercializes pharmaceutical products, with a focus on innovative therapies and equity-based incentive structures for key executives. The company utilizes its 2019 Equity Incentive Compensation Plan to align management compensation with shareholder interests and market performance.
Average Trading Volume: 4,633,873
Technical Sentiment Signal: Buy
Current Market Cap: $129.8M
Find detailed analytics on EDSA stock on TipRanks’ Stock Analysis page.